Search Results

Oncoinvent Receives FDA Fast Track Designation for Radspherin ® as Treatment for Peritoneal Carcinomatosis from Ovarian Cancer.

Oncoinvent AS today announced that members of management will participate in a virtual fireside chat at the Cantor Fitzgerald Frontiers in Radiopharma Virtual Summit on Monday, May 20, 2024 at 9:00 a.m. ET.

Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will present at the Evercore ISI 2024 Emerging Biotech Conference on Wednesday, February 28, 2024 at 11:20 a.m. ET.

Oncoinvent AS announced the appointment of newly elected members of its Board of Directors and the formation of a Scientific and Clinical Advisory Board under the leadership of founding scientists Roy Larsen and Øyvind Bruland, previous board members and leading experts in oncology and pharmaceutical development.

Oncoinvent AS today announced the appointment of Anders Månsson as Chief Executive Officer (CEO), effective September 1st , 2023.

Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for the phase 2 study for Radspherin® in patients with peritoneal carcinomatosis from ovarian cancer.

Oncoinvent AS today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for the phase 2b study for Radspherin® in patients with peritoneal carcinomatosis from colorectal cancer.